Search Videos and More
News
U.S. News & World Report Recognizes Fox Chase Cancer Center Among Nation’s Best Hospitals for Cancer Care
U.S. News & World Report has ranked Fox Chase Cancer Center among the nation’s top hospitals for cancer care according to the publication’s 2026-27 Best Hospitals rankings.
News
From Fellowship to Faculty: Building a Fox Chase Career
Arielle Weiss, MD, Assistant Professor, Department of Surgery, and Jason Conger, MD, Assistant Professor, Department of Surgery, both in the Division of Gynecologic Oncology, came to Fox Chase Cancer Center shaped by different experiences, but ultimately each found the “right fit” in choosing a gynecologic oncology fellowship at Fox Chase and later joining its faculty.
News
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
News
New Program Will Improve Patient Access to Clinical Trials
A multidisciplinary team at Fox Chase Cancer Center has developed and tested a patient-centered education program designed to reduce barriers to clinical trial participation among kidney cancer patients.
News
Combined Tests Could Reduce Unnecessary Bladder Removal
Combining a visual inspection of the bladder with a blood test to check for the presence of circulating tumor DNA can accurately predict which bladder cancer patients still have cancer in their bladder after treatment — and which do not. The findings presented today by Fox Chase Cancer Center researchers could someday help urologists identify which bladder cancer patients can safely avoid undergoing bladder removal, a risky and life-altering surgery.
News
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.
News
Fox Chase Cancer Center Celebrates Innovation, Sustained Growth, and Upward Momentum
When it comes to cancer, our work can seem insurmountable. But look closer, and it offers enduring hope. Despite the demands — or perhaps because of them — the faculty and staff at Fox Chase Cancer Center steadily rise above to achieve more.
News
The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer
Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.
News
Defeating Cancer Means Never Resting on Our Laurels
At Fox Chase Cancer Center, our faculty, fellows, and residents always look to the future to develop and collaborate on therapeutic breakthroughs to enhance life and extend it—never resting on accolades earned in the past.
News
Venturing into New Treatment Territories for Myelofibrosis with a Fox Chase Investigator-Initiated Study
The study is a phase one, single-site, dose-escalation study for patients with myeloproliferative neoplasms unresponsive to any JAK2 inhibitor. It combines two oral medications, Pacritinib and Talazoparib, and is for transplant-ineligible patients.
News
Temple University Hospital and Fox Chase Cancer Center Researchers Characterize HER2 Mutations in Patients With Lung Adenocarcinoma
Human epidermal growth factor 2 (HER2) mutations can be identified in up to 6% of non-small cell lung cancer cases where KRAS, EGFR, or ALK gene mutations are also found, according to the results of research from Temple University Hospital and Fox Chase Cancer Center presented today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
News
Fox Chase Researchers Present Data on Integrating Palliative Care Education Into Hematology-Oncology Fellowships
A new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge and skill confidence, according to results of a pilot study presented today by Fox Chase Cancer Center researchers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.